Approvals & regulatory · first seen 13h ago, updated 13h ago

WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability

1 outlet FDA

WUXI, China, Sept. 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its drug substance (DS) and drug product (DP) manufacturing facilit…

Summary from PR Newswire - Clinical Trials.

Coverage 1 article · 1 outlet

PR Newswire - Clinical Trials 13h ago
WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability